Fusion Endolysin Cecropin A Gram-Negative Bacteria
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current antibiotics are ineffective against rapidly increasing antibiotic-resistant gram-negative bacteria, particularly Pseudomonas aeruginosa, due to their ability to evade traditional antibiotic mechanisms, necessitating a new treatment approach.
Innovation Solution
Development of a mutant polypeptide and fusion protein combining endolysin with Cecropin A, engineered to enhance antibacterial activity against gram-negative bacteria, including a synergistic effect when used with standard antibiotics like colistin, by improving outer membrane permeability and antimicrobial activity.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If conventional antibiotics are used to treat gram-negative bacteria, then treatment of susceptible bacteria is effective, but treatment fails against antibiotic-resistant strains
Solution Approach 1:
The invention creates a fusion protein combining endolysin (which degrades peptidoglycan in bacterial cell walls) with Cecropin A (which disrupts outer membranes of gram-negative bacteria). This composite structure allows the protein to simultaneously target both the outer membrane and peptidoglycan layer, achieving effective killing of gram-negative bacteria including resistant strains while maintaining reliability of action through dual-mechanism activity.
2Strength
If endolysin is used to destroy bacterial cell walls, then bactericidal activity is achieved, but the outer membrane of gram-negative bacteria prevents effective access
Solution Approach 1:
The fusion protein structure positions Cecropin A at the N-terminus to first disrupt the outer membrane of gram-negative bacteria, creating access pathways. This preliminary action allows the endolysin portion of the fusion protein to subsequently reach and degrade the peptidoglycan layer, achieving effective bactericidal activity against gram-negative bacteria that would otherwise be protected by their outer membrane.
3Reliability
If antibiotic resistance increases, then survival of bacterial strains improves, but treatability with existing antibiotics deteriorates
Solution Approach 1:
The invention uses a phage-derived endolysin as a template for creating an antibiotic alternative. By copying the cell wall-degrading mechanism from bacteriophages and combining it with membrane-disrupting cecropin, the invention creates a new class of antimicrobial that bypasses conventional antibiotic resistance mechanisms, restoring treatability of resistant bacterial strains.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The engineered endolysin, LNT113, demonstrates enhanced antibacterial efficacy against gram-negative bacteria, including resistant strains, with a synergistic effect observed when combined with colistin, offering a potential solution to the growing problem of antibiotic resistance.
Implementation Method 1
using endolysin, a protein of the bacteriophage, to destroy the cell wall of the host bacterium
Implementation Method 2
by improving outer membrane permeability and antimicrobial activity
Data Source
AI summary
Provided are a novel polypeptide having endolysin activity, a fusion protein comprising the polypeptide and an antibiotic active protein, and an antibiotic use against a gram-negative pathogen of the polypeptide and/or fusion protein and/or a use for prevention and/or treatment of gram-negative pathogen infection and/or disease or symptoms related to gram negative pathogen infection.